Ou H, Chen Z, Xiang L, et al. Frizzled 2‐induced epithelial‐mesenchymal transition correlates with vasculogenic mimicry, stemness, and Hippo signaling in hepatocellular carcinoma. Cancer Sci. 2019;110:1169--1182. 10.1111/cas.13949

Ou and Chen equally contributed to this study.

CSC

:   cancer stem cell

DEG

:   differentially expressed gene

EMT

:   epithelial‐mesenchymal transition

FDR

:   false discovery rate

FZD

:   Frizzled

HBV

:   hepatitis B virus

HCC

:   hepatocellular carcinoma

IHC

:   immunohistochemical

LATS1

:   large tumor suppressor kinase 1

MST1/2

:   mammalian sterile 20‐like kinase 1/2

NC

:   negative control

PAS

:   periodic acid‐Schiff

qRT‐PCR

:   quantitative RT‐PCR

RNA‐Seq

:   RNA sequencing

SOX2

:   SRY‐box 2

TAZ

:   Tafazzin

VM

:   vasculogenic mimicry

YAP

:   yes‐associated protein

1. INTRODUCTION {#cas13949-sec-0001}
===============

Hepatocellular carcinoma represents the sixth most common malignancy in the world and the third leading cause of cancer‐related deaths worldwide, with particularly high morbidity in China due to the high incidence of HBV infection.[1](#cas13949-bib-0001){ref-type="ref"} Although HCC is curable if detected early, most patients are diagnosed in the advanced stage and have an unfavorable outcome.[2](#cas13949-bib-0002){ref-type="ref"} Tumor metastasis and recurrence are the principal causes accounting for poor outcomes.[3](#cas13949-bib-0003){ref-type="ref"} The clinical stage, based on the Barcelona Clinic Liver Cancer and TNM classification systems, is currently the most common prognostic factor at the time of diagnosis, but the molecular mechanism involved in HCC progression and metastasis is still unclear.[4](#cas13949-bib-0004){ref-type="ref"} Thus, novel prognostic biomarkers and promising therapeutic targets that are associated with HCC progression and metastasis would be of great clinical significance.

Wnt proteins are a family of transcriptional genes that play pivotal roles in cell survival, migration, and invasion by coordinating with one or more of the FZD receptors.[5](#cas13949-bib-0005){ref-type="ref"} Multiple studies have reported that the canonical Wnt/β‐catenin signaling pathway is activated during EMT.[6](#cas13949-bib-0006){ref-type="ref"}, [7](#cas13949-bib-0007){ref-type="ref"}, [8](#cas13949-bib-0008){ref-type="ref"} Among them, a study has revealed that FZD2 drives EMT and cell metastasis through a previously unrecognized, noncanonical pathway that involves molecules such as the tyrosine kinase (FYN) and STAT3.[9](#cas13949-bib-0009){ref-type="ref"} Another study confirmed that FZD2 upregulation was significantly correlated with EMT status in HCC.[10](#cas13949-bib-0010){ref-type="ref"}

Epithelial‐mesenchymal transition has been associated with CSC properties and VM in several tumors.[11](#cas13949-bib-0011){ref-type="ref"}, [12](#cas13949-bib-0012){ref-type="ref"}, [13](#cas13949-bib-0013){ref-type="ref"} Cancer stem cells are a small subgroup within tumors that are capable of self‐renewal and maintain tumor‐initiating capacity through differentiation into the heterogeneous nature of tumor cells that comprise the primary tumor. They also provide the possibility for cells that cause tumor recurrence and drug resistance. Increasing evidence indicates that VM, the formation of a vascular‐like structure that mimics the embryonic vascular network pattern to support tumor tissue, is a critical step in tumor progression, invasion, and metastasis. Since the discovery of VM, research has been carried out on the molecular mechanism by which VM formation emerges, in an effort to identify valuable therapeutic targets. The noncanonical Wnt signaling pathway, which provides important clues to tumorigenesis, is implicated in both VM and CSCs,[14](#cas13949-bib-0014){ref-type="ref"}, [15](#cas13949-bib-0015){ref-type="ref"}, [16](#cas13949-bib-0016){ref-type="ref"} and thus is of great concern. In this study, we found that FZD2 might be implicated in EMT‐mediated metastasis and CSC maintenance, as well as VM through interacting with Hippo signaling, in HCC. Our study provides a plausible mechanism for HCC metastasis and early recurrence.

2. MATERIALS AND METHODS {#cas13949-sec-0002}
========================

2.1. Patients and tissue samples {#cas13949-sec-0003}
--------------------------------

Two independent cohorts, each consisting of 100 HCC patients with HCC, were enrolled in this study. Patient inclusive criteria were as follows: (a) pathologically diagnosed with HCC; (b) received radical resection in the Department of Hepatobiliary Surgery at Nanfang Hospital of Southern Medical University (Guangzhou, China) between 2010 and 2015; (c) without a history of any antitumor treatment; and (d) with complete medical record and follow‐up data. In cohort 1, fresh HCC tissue samples and adjacent noncancerous tissues from 100 patients were used for qRT‐PCR. In cohort 2, paraformaldehyde‐fixed, paraffin‐embedded tissues from 100 patients were used for IHC staining. This study was approved by the ethics committee of Nanfang Hospital of Southern Medical University. Patients' samples were collected after informed consent in accordance with the Declaration of Helsinki.

2.2. Cell lines {#cas13949-sec-0004}
---------------

Hepatocellular carcinoma cell lines SNU387, SNU449, and HepG2 were obtained from the ATCC (Manassas, VA, USA). The cells were cultured in RPMI‐1640 (SNU387 and SNU449) or DMEM (HepG2) (Corning, Logan, UT, USA) supplemented with 10% FBS (Corning) at 37°C in a humidified 5% CO~2~ incubator.

2.3. Animals {#cas13949-sec-0005}
------------

Male BALB/c‐nude mice (4‐6 weeks old) were obtained from the Central Laboratory of Animal Science, Southern Medical University (Guangzhou, China) and were raised under specific pathogen‐free conditions. Animal experiments were carried out in accordance with the Guide for the Care and Use of Laboratory Animals, which were approved by the Institutional Animal Care and Use Committee of Southern Medical University.

2.4. Quantitative RT‐PCR analysis {#cas13949-sec-0006}
---------------------------------

Total RNA was extracted using the RNAiso reagent (TaKaRa, Dalian, China). Quantitative PCR was carried out using the SYBR Premix Ex Taq kit (TaKaRa) following the manufacturer\'s instructions. Results were normalized to the expression levels of GAPDH. Primers sequences were as follows: FZD2 forward primer, 5′‐TCC TCA AGG TGC CAT CCT ATC TC ‐3′ and reverse primer, 5′‐TGG TGA CAG TGA AGA AGG TGG AAG‐3′; and GAPDH forward primer, 5′‐ CAG GAG GCA TTG CTG ATG AT‐3′ and reverse primer, 5′‐GAA GGC TGG GGC TCA TTT‐3′. The qRT‐PCR assay results were analyzed by the 2^−ΔΔCT^ method.[17](#cas13949-bib-0017){ref-type="ref"}

2.5. Immunohistochemistry staining {#cas13949-sec-0007}
----------------------------------

Immunohistochemistry staining was undertaken as described in our previous report.[18](#cas13949-bib-0018){ref-type="ref"} The expression of FZD2 was examined by light microscopy by evaluating 1000 cells in 5 fields to obtain the percentage of positive cells, which was multiplied by staining intensity to produce a weighted score for each case. Cases with a weighted score of 0‐3 were regarded negative and those with a score of 4‐8 positive. Primary Abs are listed in [Table S1](#cas13949-sup-0003){ref-type="supplementary-material"}.

2.6. CD34/PAS double staining {#cas13949-sec-0008}
-----------------------------

To display the VM structures in HCC human samples and mouse xenografts, histological sections were IHC stained for CD34, then stained with PAS (cat. BA4080A; BASO, Zhuhai, China) following the manufacturer\'s instructions.

2.7. Small interfering RNA transient transfection {#cas13949-sec-0009}
-------------------------------------------------

For transient FZD2 silencing, SNU387 and SNU449 cells were transfected with siRNAs (GenePharma, Shanghai, China) in 6‐well plates for 48 hours. The siRNA sequences were as follows: siRNA‐1 (targeting 5′‐TCT CAA CTG CTT TGC TCC CAT CAA T‐3′), siRNA‐2 (targeting 5′‐GCC AGG TGG TCA TGC TCA ACT ACA A‐3′), and NC (targeting 5′‐TTC TCC GAA CGT GTC ACG TTT‐3′).

2.8. Lentiviral construction and cell transfection {#cas13949-sec-0010}
--------------------------------------------------

The U6‐sh‐FZD2‐UFC1‐CMV‐GFP lentiviral vector was purchased from Genechem (Shanghai, China) and was used to stably knock down FZD2 expression. A negative control lentiviral vector containing nonsilencing shRNA was used. SNU449 cells were infected with either of the lentiviral vectors at an MOI of 20. To generate clones stably overexpressing FZD2, HepG2 cells were infected at an MOI of 40 with a lentiviral vector harboring a full‐length human FZD2 sequence or empty lentiviral vector control.

2.9. Cell viability assay {#cas13949-sec-0011}
-------------------------

Cells (1 × 10^3^/well) were seeded in 96‐well plates and cell viability was evaluated from 6 replicates with the CCK‐8 (Dojindo Laboratories, Kumamoto, Japan) at 0, 24, 48, 72, and 96 hours after siRNA transfection.

2.10. Flow cytometric analysis {#cas13949-sec-0012}
------------------------------

For the apoptosis assay, cells (1 × 10^6^) were stained with annexin V‐APC (allophycocyanin) and DAPI (Apoptosis Detection Kit; KeyGEN, Nanjing, China) and analyzed with a flow cytometer (BD Biosciences, San Diego, CA, USA). To identify the CD44^+^ subpopulation, cells were labeled with a phycoerythrin‐conjugated anti‐CD44 Ab (eBioscience, San Diego, CA, USA). Cells incubated without labeled Ab were used as NC. Cells were incubated with 5 μL Ab at room temperature for 30 minutes before detection on a flow cytometer. The data were analyzed using FlowJo software (Tree Star, Ashland, OR, USA).

2.11. Migration and invasion assays {#cas13949-sec-0013}
-----------------------------------

For migration assay, cells (5 × 10^4^) were resuspended in serum‐free medium and then cultured in the upper chamber of a Transwell insert (8‐μm pore size; Millipore, Billerica, MA, USA). For invasion assay, cells (5 × 10^4^) were resuspended in serum‐free medium and then cultured in the upper chamber of an insert coated with 100% Matrigel. Complete medium with 10% FBS was added to the lower chamber. After incubation for 24‐48 hours, the cells that had migrated or invaded through the membrane were stained with 0.1% crystal violet and photographed under an inverted microscope.

2.12. Western blot analysis {#cas13949-sec-0014}
---------------------------

Cells were lysed with RIPA buffer (Beyotime, Jiangsu, China) containing 1 mM PMSF. Equivalent total protein (30 μg) was separated by 10% SDS‐PAGE. The separated proteins were transferred to a PVDF membrane. The membrane was trimmed and blocked with 5% BSA for 1 hour, and probed with primary Abs ([Table S1](#cas13949-sup-0003){ref-type="supplementary-material"}) overnight at 4°C. Then the membranes were incubated with corresponding HRP‐conjugated secondary Abs diluted in blocking buffer for 1 hour at 37°C. Protein immunocomplexes were visualized by an enhanced chemiluminescence detection agent (Beyotime). The membrane was scanned by Quantity One (Bio‐Rad, Hercules, CA, USA). To evaluate the nuclear fractions of YAP, a nuclear‐cytosol extraction kit (FDbio Science, Hangzhou, China) was used. Histone H3 was used as a loading control for nuclear protein.

2.13. Three‐dimensional tube formation assay {#cas13949-sec-0015}
--------------------------------------------

A 3D culture was used to assess the ability of tumor cells to form a VM structure. Cells (2 × 10^4^) were resuspended in a 200‐μL mixture of equal volumes of serum‐free DMEM or RPMI‐1640 medium, and then placed into 60% Matrigel‐coated 96‐well plates. After incubation for 4 hours at 37°C, the branch points of the formed tubes, which represented the degree of VM formation, were quantitated under an inverted microscope.

2.14. Tumorigenicity assay {#cas13949-sec-0016}
--------------------------

To establish an s.c. xenograft model, 10 male BALB/c nude mice at 5‐6 weeks of age were used. Stable knockdown and overexpressing HCC cell lines were injected s.c. into the posterior‐lateral side of each mouse. Tumor growth was recorded every 5 days till 30 days. The length (*L*) and width (*W*) of the tumor was measured and the tumor volume (*V*) was calculated with the formula: *V* = *L* × *W* ^2^ × π/6. Tumor samples were fixed in paraformaldehyde and embedded in paraffin for IHC staining.

2.15. RNA sequencing analysis {#cas13949-sec-0017}
-----------------------------

Total RNA for RNA‐Seq was isolated from SNU449 cells infected with either of the lentiviral vectors encoding specific shRNA sequences or the NC vector. Total RNA was quantified and integrity was measured on a BioAnalyzer 2100 (Agilent, Santa Clara, CA, USA). Oligo(dT) magnetic beads were used to select mRNA with polyA tail and the target RNA was obtained after purification. The RNA was fragmented and reverse‐transcribed into double‐stranded cDNA using N6 random primer. The double‐stranded cRNA was processed for end repair and was then ligated with adaptor and amplified by PCR. The PCR products were denatured by heating and the single‐stranded cDNA was cyclized using splint oligo and DNA ligase. The cDNA library was sequenced by BGISEQ‐500 (BGI, Shenzhen, China). After primary sequencing data passed quality control, the raw reads were filtered to obtain clean reads, which were aligned to the reference genome using HISAT and to reference gene sequences using Bowtie2. Gene expression was quantified by RSEM. Differentially expressed genes between FZD2 shRNA‐transfected versus control cells were screened using the Poisson distribution method. We used FDR ≤ .001 and \|Log~2~Ratio\| ≥1 as thresholds to judge the significance of gene expression difference. Differentially expressed genes were subjected to Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis.

2.16. Statistical analysis {#cas13949-sec-0018}
--------------------------

All experiments were carried out in triplicate and data are presented as the mean ± standard deviation. Means were compared by Student\'s *t* test or one‐way ANOVA with either SPSS 19.0 software (SPSS, Chicago, IL, USA) or GraphPad Prism 5 (GraphPad Software, La Jolla, CA, USA). Survival curves were calculated using the Kaplan‐Meier method. Differences were considered statistically significant when *P \< *.05.

3. RESULTS {#cas13949-sec-0019}
==========

3.1. Upregulation of FZD2 in HCC tissues predicts tumor progression and poor survival {#cas13949-sec-0020}
-------------------------------------------------------------------------------------

We evaluated FZD2 expression in HCC tissues from 2 cohorts of patients with HCC. In cohort 1, we analyzed FZD2 expression by qRT‐PCR in 100 pairs of HCC/nontumor tissues, and we found that the FZD2 mRNA level was significantly higher in HCC tissues than in adjacent nontumor tissues (*P *=* *.0411; Figure [1](#cas13949-fig-0001){ref-type="fig"}A,B). The elevated FZD2 expression was confirmed by IHC staining of an additional 100 pairs of paraffin‐embedded HCC/noncancerous specimens from cohort 2. The results showed the upregulation of FZD2 in HCC and suggested that FZD2 is localized in the cytoplasm of cancer cells (*P *\<* *.01; Figure [1](#cas13949-fig-0001){ref-type="fig"}C,D).

![Frizzled 2 (FZD2) is overexpressed in hepatocellular carcinoma (HCC) tissues and predicts poor survival for patients with HCC. A, FZD2 mRNA expression was analyzed by quantitative RT‐PCR in HCC tissues and adjacent nontumor tissues (cohort 1, n = 100). \**P *\<* *.05. B, FZD2 was upregulated in 61/100 (61%) of HCC cases. Data are presented as the log~2~ ratio of the FZD2 mRNA level in HCC tissues versus that in adjacent nontumorous tissues. C, FZD2 protein expression was detected by immunohistochemical staining (cohort 2, n = 100). D, Representative images of immunohistochemical staining for FZD2 in HCC tissues. E,F, Kaplan‐Meier analysis of relapse‐free survival in HCC patients from cohort 1 (*P *=* *.0007) and cohort 2 (*P *=* *.0137). Differences were assessed by log‐rank test. G,H, Kaplan‐Meier analysis of overall survival in HCC patients from cohort 1 (*P *=* *.0365) and cohort 2 (*P *=* *.0209). Differences were assessed by log‐rank test. \*\**P *\<* *.01](CAS-110-1169-g001){#cas13949-fig-0001}

We then analyzed the association between FZD2 and clinicopathologic parameters in HCC patients. Statistical analysis indicated a strong correlation between FZD2 expression and tumor size (*P *=* *.028 and *P *=* *.010, in cohorts 1 and 2, respectively), differentiation (*P *=* *.013 and *P *=* *.005), portal vein tumor thrombus (*P *=* *.046 and *P *=* *.000), microvascular invasion (*P *=* *.006 and .010), TNM stage (*P *=* *.045 and *P *=* *.031), Barcelona Clinic Liver Cancer stage (*P *=* *.032 and *P *=* *.005), metastasis (*P *=* *.028 and *P *=* *.001), and early recurrence (*P *=* *.003 and *P *=* *.009) (Tables [1](#cas13949-tbl-0001){ref-type="table"} and [2](#cas13949-tbl-0002){ref-type="table"}). Kaplan‐Meier analysis suggested a positive correlation between cancerous FZD2 expression and significantly reduced relapse‐free survival and overall survival (all *P *\<* *.05; Figure [1](#cas13949-fig-0001){ref-type="fig"}E‐H).

###### 

Clinicopathologic characteristics of 100 patients with hepatocellular carcinoma: fresh tissue samples from cohort 1 assessed by quantitative RT‐PCR

  Feature                                                   N    FZD2 mRNA expression level   *P* value[b](#cas13949-note-0013){ref-type="fn"}   
  --------------------------------------------------------- ---- ---------------------------- -------------------------------------------------- ----------
  Sex                                                                                                                                            
  Male                                                      90   46                           44                                                 .505
  Female                                                    10   6                            4                                                  
  Age, y                                                                                                                                         
  \<60                                                      85   44                           41                                                 .401
  ≥60                                                       15   6                            9                                                  
  AFP level, μg/L                                                                                                                                
  \<400                                                     59   28                           31                                                 .542
  ≥400                                                      41   22                           19                                                 
  Cirrhosis                                                                                                                                      
  Yes                                                       72   40                           32                                                 .075
  No                                                        28   10                           18                                                 
  Tumor capsule                                                                                                                                  
  Present                                                   74   35                           39                                                 .362
  Absent                                                    26   15                           11                                                 
  Tumor size, cm                                                                                                                                 
  \<5                                                       53   21                           32                                                 **.028**
  ≥5                                                        47   29                           18                                                 
  Tumor number                                                                                                                                   
  Solitary                                                  79   39                           40                                                 **.028**
  Multiple                                                  21   10                           11                                                 
  Differentiation                                                                                                                                
  Well                                                      13   2                            11                                                 **.013**
  Moderate                                                  61   31                           30                                                 
  Poor                                                      26   17                           9                                                  
  PVTT                                                                                                                                           
  Present                                                   20   14                           6                                                  **.046**
  Absent                                                    80   36                           44                                                 
  MVI                                                                                                                                            
  Present                                                   33   23                           10                                                 **.006**
  Absent                                                    67   27                           40                                                 
  TNM stage                                                                                                                                      
  I+II                                                      46   18                           28                                                 **.045**
  III+IV                                                    54   32                           22                                                 
  BCLC stage                                                                                                                                     
  A                                                         43   18                           28                                                 **.032**
  B                                                         9    32                           22                                                 
  C                                                         48   30                           18                                                 
  Metastasis                                                                                                                                     
  Yes                                                       51   31                           20                                                 **.028**
  No                                                        49   19                           30                                                 
  Early recurrence[a](#cas13949-note-0003){ref-type="fn"}                                                                                        
  Yes                                                       35   24                           11                                                 **.003**
  No                                                        59   22                           37                                                 

Defined as relapse‐free time \<12 months, and 6 cases were lost to follow‐up.

Values in bold indicated statistically significant.

AFP, α‐fetoprotein; BCLC, Barcelona Clinic Liver Cancer; MVI, microvascular invasion; PVTT, portal vein tumor thrombus.

John Wiley & Sons, Ltd

###### 

Clinicopathologic characteristics of 100 patients with hepatocellular carcinoma: paraformaldehyde‐fixed, paraffin‐embedded tissues from cohort 2 assessed by immunohistochemical staining

  Feature                                                   N    FZD2 protein expression level   *P* value[b](#cas13949-note-0023){ref-type="fn"}   
  --------------------------------------------------------- ---- ------------------------------- -------------------------------------------------- -----------
  Sex                                                                                                                                               
  Male                                                      82   46                              36                                                 0.411
  Female                                                    18   12                              6                                                  
  Age, year                                                                                                                                         
  \<60                                                      84   50                              34                                                 0.479
  ≥60                                                       16   8                               8                                                  
  AFP level, μg/L                                                                                                                                   
  \<400                                                     66   35                              31                                                 0.161
  ≥400                                                      34   23                              11                                                 
  Cirrhosis                                                                                                                                         
  Yes                                                       60   41                              19                                                 **0.010**
  No                                                        40   17                              23                                                 
  Tumor capsule                                                                                                                                     
  Present                                                   42   23                              19                                                 0.577
  Absent                                                    58   35                              23                                                 
  Tumor size, cm                                                                                                                                    
  \<5                                                       50   21                              29                                                 **0.001**
  ≥5                                                        50   31                              13                                                 
  Tumor number                                                                                                                                      
  Solitary                                                  84   47                              37                                                 0.342
  Multiple                                                  16   11                              5                                                  
  Differentiation                                                                                                                                   
  Well                                                      13   6                               8                                                  **0.005**
  Moderate                                                  61   37                              33                                                 
  Poor                                                      26   15                              1                                                  
  PVTT                                                                                                                                              
  Present                                                   47   40                              7                                                  **0.000**
  Absent                                                    53   18                              35                                                 
  MVI                                                                                                                                               
  Present                                                   60   41                              19                                                 **0.010**
  Absent                                                    40   17                              23                                                 
  TNM stage                                                                                                                                         
  I+II                                                      64   32                              32                                                 **0.031**
  III+IV                                                    36   26                              10                                                 
  BCLC stage                                                                                                                                        
  A                                                         60   27                              33                                                 **0.005**
  B                                                         10   8                               2                                                  
  C                                                         30   23                              7                                                  
  Metastasis                                                                                                                                        
  Yes                                                       48   36                              12                                                 **0.001**
  No                                                        52   22                              30                                                 
  Early recurrence[a](#cas13949-note-0005){ref-type="fn"}                                                                                           
  Yes                                                       39   28                              11                                                 **0.009**
  No                                                        56   25                              31                                                 

Defined as relapse‐free time \<12 months, and 5 cases were lost to follow‐up.

Values in bold indicated statistically significant.

AFP, α‐fetoprotein; BCLC, Barcelona Clinic Liver Cancer; MVI, microvascular invasion; PVTT, portal vein tumor thrombus.

John Wiley & Sons, Ltd

3.2. Frizzled 2 promotes cell proliferation, inhibits cell apoptosis, and enhances cell migration and invasion in HCC {#cas13949-sec-0021}
---------------------------------------------------------------------------------------------------------------------

We explored the potential role of FZD2 in the development and progression of HCC. To this end, we transiently silenced FZD2 expression in SNU387 and SNU449 cell lines for in vitro loss‐of‐function experiments; we also established a HepG2 cell line stably overexpressing FZD2 and a SNU449 cell line with stable FZD2 depletion for in vivo experiments. Silencing and overexpression were confirmed by qRT‐PCR and western blot analysis (Figure [2](#cas13949-fig-0002){ref-type="fig"}A). A CCK‐8 assay revealed that FZD2 depletion inhibited the proliferative capacity of SNU387 and SNU449 cells compared with that of control cells. Overexpression of FZD2 dramatically enhanced the proliferative capacity of HepG2 cells (Figure [2](#cas13949-fig-0002){ref-type="fig"}B). The growth inhibition effect was confirmed in vivo by a tumor growth assay. Xenograft tumors grown from FZD2‐knockdown SNU449 cells had lower weights and volumes than tumors grown from control cells. Tumors derived from FZD2‐overexpressing cells were larger than control ones (Figure [2](#cas13949-fig-0002){ref-type="fig"}B). These results indicated that FZD2 might facilitate HCC cell proliferation both in vitro and in vivo.

![Frizzled 2 (FZD2) promotes hepatocellular carcinoma cell proliferation in vitro and in vivo. A, Knockdown of FZD2 in SNU387 and SNU449 cells and overexpression of FZD2 were confirmed by quantitative RT‐PCR and western blot analysis. B, Cell growth was determined by CCK‐8 assay. C, Tumor size (left panels), weight (middle panels), and volume (right panels) of xenografts harvested at 30 days after s.c. injection of FZD2‐knockdown SNU449 cells and FZD2‐overexpressing HepG2 cells in nude mice. \**P *\<* *.05, \*\**P *\<* *.01. NC, negative control](CAS-110-1169-g002){#cas13949-fig-0002}

To determine whether FZD2 might be critical for tumor survival, we evaluated apoptosis by FACS analysis in HCC cells stained with annexin V. We found that FZD2‐knockdown SNU387 and SNU449 cells had a significantly higher proportion of annexin V‐positive cells than cells transfected with NC‐siRNA, whereas a significant decrease in annexin V‐positive cells was observed in FZD2‐overexpressing HepG2 cells (Figure [3](#cas13949-fig-0003){ref-type="fig"}A,B).

![Frizzled 2 (FZD2) inhibits hepatocellular carcinoma cell apoptosis and enhances hepatocellular carcinoma cell migration and invasion. A,B, Percentages of apoptotic cells with annexin V staining were analyzed by flow cytometry. C,D, Numbers of migrated and invaded cells were tested by Transwell assays. \**P *\<* *.05, \*\**P *\<* *.01. NC, negative control](CAS-110-1169-g003){#cas13949-fig-0003}

To determine the role of FZD2 in tumor metastasis, Transwell assays were carried out. Knockdown of FZD2 markedly decreased the migratory and invasion capacities of SNU387 and SNU449 cells (Figure [3](#cas13949-fig-0003){ref-type="fig"}C). Furthermore, FZD2‐overexpressing HepG2 cells showed stronger migratory and invasive abilities than the control group (Figure [3](#cas13949-fig-0003){ref-type="fig"}D). These results indicated a positive correlation between FZD2 expression and aggression of HCC.

3.3. Frizzled 2 drives EMT in HCC {#cas13949-sec-0022}
---------------------------------

Epithelial‐mesenchymal transition plays a vital role in cancer metastasis and progression. The loss of E‐cadherin expression and the gain of N‐cadherin and Vimentin expression represents the molecular event of EMT. Therefore, we determined the levels of these EMT markers in FZD2‐knockdown and ‐overexpressing cells. Knockdown of FZD2 induced expression of E‐cadherin and suppressed that of N‐cadherin, Vimentin, Snail, and Slug, whereas overexpression of FZD2 attenuated E‐cadherin expression and promoted N‐cadherin, vimentin, Snail, and Slug expression (Figure [4](#cas13949-fig-0004){ref-type="fig"}A). Similar effects were observed by IHC staining of xenograft tumor tissues ([Figure S1](#cas13949-sup-0001){ref-type="supplementary-material"}).

![Frizzled 2 (FZD2) induces epithelial‐mesenchymal transition and maintains cancer stem cell properties of hepatocellular carcinoma cells. A, Epithelial‐mesenchymal transition‐related proteins E‐cadherin, N‐cadherin, Vimentin, Snail, and Slug were detected by western blot analysis. B, Percentage of CD44^+^ cells were analyzed by flow cytometry. C, Nanog and SOX2 protein were detected by western blot analyses. \**P *\<* *.05, \*\**P *\<* *.01. NC, negative control](CAS-110-1169-g004){#cas13949-fig-0004}

3.4. Frizzled 2 increases stem‐like properties of HCC {#cas13949-sec-0023}
-----------------------------------------------------

The recent discovery that CSCs emerge, in part, as a result of EMT has provided a new understanding of the regulatory mechanisms in CSCs.[19](#cas13949-bib-0019){ref-type="ref"} To identify the stemness phenotype, we assessed the expression of the CSC‐specific surface marker CD44. Flow cytometric analysis showed that knockdown of FZD2 in SNU387 and SNU449 cells resulted in a significant reduction in the CD44^+^ subpopulation, and overexpression of FZD2 promoted the CD44^+^ subpopulations in HepG2 cells (Figure [4](#cas13949-fig-0004){ref-type="fig"}B). In addition, we examined the expression of 2 transcription factors that are characteristic of pluripotent cells: Nanog and SOX2. Following knockdown of FZD2 in SNU387 and SNU449 cells, Nanog and SOX2 were downregulated (Figure [4](#cas13949-fig-0004){ref-type="fig"}C). Overexpression of FZD2 in HepG2 cells brought about an opposite effect (Figure [4](#cas13949-fig-0004){ref-type="fig"}C). The effect of FZD2 on Nanog and SOX2 expression was further supported by IHC staining in xenograft tumor tissues ([Figure S1](#cas13949-sup-0001){ref-type="supplementary-material"}). These findings supported that FZD2 regulated the CSCs feature of HCC cells.

3.5. Frizzled 2 promotes VM formation of HCC cells {#cas13949-sec-0024}
--------------------------------------------------

With the increasing knowledge about CSC phenotypes and functions, the CSCs concept has been applied to VM, which has also been recently observed in HCC.[20](#cas13949-bib-0020){ref-type="ref"} To elucidate the effect of FZD2 on VM, we evaluated the relationship between FZD2 expression and VM structures in clinical samples. Vasculogenic mimicry structures were visualized by CD34/PAS double staining and were identified as vascular‐like channels that were lined by tumor cells, displayed positive staining for PAS but negative staining for CD34 (PAS^+^CD34^−^), and possibly contained erythrocytes (Figure [5](#cas13949-fig-0005){ref-type="fig"}A). The presence of a VM structure in an HCC section was designated as VM+, and cases without a VM structure in a whole HCC section were considered VM− cases. There were more VM+ cases in the FZD2^+^ group than in the FZD2^−^ group (*P *\<* *.01; Figure [5](#cas13949-fig-0005){ref-type="fig"}B). These data suggested a positive correlation between FZD2 and VM in clinical specimens. To gain further insight into the correlation between FZD2 expression and VM, a 3D tube formation assay was carried out. As shown in Figure [5](#cas13949-fig-0005){ref-type="fig"}C, both SNU387 and SNU449 cells could form typical channels in the in vitro 3D culture model, but the number of branch points decreased when the cells were transfected with FZD2 siRNA. Moreover, compared with the control group, HepG2 cells overexpressing FZD2 formed more tube‐like structures, and the inner walls of these pipes were smoother. Vasculogenic mimicry structures were also evaluated in the xenograft tumor tissues. In agreement with the results of 3D culture, PAS^+^/CD34^−^ structures were decreased in the FZD2‐depleted cells and were increased in the FZD2‐overexpressing cells as compared with their corresponding controls ([Figure S2](#cas13949-sup-0002){ref-type="supplementary-material"}). Collectively, the in vitro and in vivo data indicated that FZD2 promotes VM of HCC cells.

![Frizzled 2 (FZD2) confers hepatocellular carcinoma (HCC) cells with vasculogenic mimicry (VM) ability. A, Representative images of VM with H&E staining in HCC tissues from cohort 2. The VM channel was periodic acid‐Schiff (PAS)^+^, but it did not express CD34. Endothelium‐dependent vessel was CD34^+^. B, FZD2 expression is positively correlated with the existence of a VM structure in HCC tissues from cohort 2. C, Representative images of tube formation by FZD2‐knockdown SNU387 and SNU449 cells and FZD2‐overexpressing HepG2 cells after 3D culture; numbers of tube‐like structures are shown. \**P *\<* *.05, \*\**P *\<* *.01. NC, negative control](CAS-110-1169-g005){#cas13949-fig-0005}

3.6. Frizzled 2 is a regulator of HCC cell invasion and metastasis by activating the Hippo‐YAP pathway {#cas13949-sec-0025}
------------------------------------------------------------------------------------------------------

To determine the gene networks underlying the biological consequences of FZD2 knockdown, RNA‐Seq analysis was carried out. In SNU449 cells transfected with FZD2 shRNA, a total of 4119 genes were differentially expressed (2563 upregulated and 1556 downregulated genes, with \|Log~2~Ratio\| ≥1 and an adjusted *P* value \[FDR *Q* value\] \< .001; Figure [6](#cas13949-fig-0006){ref-type="fig"}A). Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of DEGs revealed that *FZD2* gene networks were closely related to the Hippo pathway (Figure [6](#cas13949-fig-0006){ref-type="fig"}B). To validate whether the Hippo pathway is involved in FZD2 dysregulation, YAP activity and TAZ levels were evaluated. Yes‐associated protein activity is determined by its phosphorylation status and cellular localization. Following phosphorylation, YAP is translocated from the nucleus to the cytoplasm for proteasome‐mediated degradation.[19](#cas13949-bib-0019){ref-type="ref"}, [20](#cas13949-bib-0020){ref-type="ref"} We also measured the cytosolic kinases upstream of YAP including LATS1, which phosphorylates and inhibits YAP, and MST1/2, which phosphorylates and activates LATS1, and the phosphorylation level of YAP. As shown in Figure [6](#cas13949-fig-0006){ref-type="fig"}C, FZD2 knockdown significantly increased the expression levels of LATS1, MST1/2, and the phosphorylation level of YAP (p‐YAP^ser127^) in SNU387 and SNU449 cells. In contrast, FZD2 overexpression suppressed these proteins in HepG2 cells. Furthermore, FZD2 knockdown resulted in a marked loss of nuclear YAP in SNU387 and SNU449 cells, whereas an increase in nuclear YAP was observed in HepG2 cells overexpressing FZD2 (Figure [6](#cas13949-fig-0006){ref-type="fig"}D). The expression levels of total YAP and TAZ were consistent with the level of nuclear YAP (Figure [6](#cas13949-fig-0006){ref-type="fig"}C). These data indicated that the tumorigenic effects of FZD2 in HCC might depend on the activity of YAP involved in the Hippo signaling pathway.

![RNA sequencing reveals that the Hippo signaling pathway is enriched following stable silencing of Frizzled 2 (FZD2) in SNU449 cells. A, Volcano plot of differentially expressed genes (DEGs). Each dot represents a DEG. Significant DEGs (false discover rate \[FDR\] ≤ .001 and \|Log2Ratio\| ≥1) are indicated in red and nonsignificant DEGs in black. B, Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis of DEGs. C, Mammalian sterile 20‐like kinase (MST)1, MST2, large tumor suppressor kinase (LATS)1, phosphorylated Yes‐associated protein (p‐YAP), total YAP, and Tafazzin (TAZ) were detected by western blot analysis. D, Nuclear YAP was detected by western blot analysis. NC, negative control](CAS-110-1169-g006){#cas13949-fig-0006}

4. DISCUSSION {#cas13949-sec-0026}
=============

In a previous study, Gujral et al[9](#cas13949-bib-0009){ref-type="ref"} reported that FZD2 is upregulated in poorly differentiated mesenchymal cancers, that FZD2 regulates EMT and migration, and that use of a blocking Ab against FZD2 was sufficient to abrogate metastases in a xenograft model. Similarly, Asano et al reported that mRNA levels of FZD2 were prognostic in a cohort of 100 patients and were associated with the EMT phenotype. Our study extends their findings based on 2 cohorts of HCC patients with HBV infection, and provides a full understanding of the clinical implications at both the mRNA and protein levels. We found that FZD2 was frequently upregulated in HCC tissues relative to corresponding adjacent nontumor tissues at both the transcriptional and the translational level. High expression of FZD2 was associated with tumor progression and poor outcome of patients with HCC and should be considered as a promising prognostic biomarker for this disease. We also confirmed the importance of FZD2‐mediated EMT on more malignant biological properties of HCC including CD44 phenotypic stemness and VM formation, reinforcing the view that EMT is a fundamental event.

Recent studies show that EMT can confer tumor cells with stem cell‐like characteristics.[21](#cas13949-bib-0021){ref-type="ref"}, [22](#cas13949-bib-0022){ref-type="ref"} In prostate cancer, recent evidence suggested that transforming growth factor‐β‐induced EMT was mechanistically linked to the formation of highly tumorigenic prostate cancer stem cells with a mesenchymal phenotype, and involved in the upregulation of Snail and Nanog.[23](#cas13949-bib-0023){ref-type="ref"} Enhanced self‐renewal, tumor‐initiating capacity, and chemoresistance have been attributed to subsets of cancer cells with high CD44 expression in HCC.[24](#cas13949-bib-0024){ref-type="ref"} Studies in breast cancer indicated that EMT might promote conversion of a subset of cancer cells defined by low CD44 expression to those with high CD44 expression.[19](#cas13949-bib-0019){ref-type="ref"}, [21](#cas13949-bib-0021){ref-type="ref"} An effort has been made in our study to bridge CD44 stem‐like subsets with aberrant FZD2 levels by FACS analysis. Further experiments suggested that FZD2 might confer HCC cells with CD44 stem‐like properties by regulating the activity of Nanog and SOX. Interestingly, our results in RNA‐Seq also revealed that *FZD2* gene networks were significantly associated with signaling pathways regulating the pluripotency of stem cells. In all, we can assume that the action of FZD2‐mediated EMT could be involved in the acquisition of CSC characteristics.

Maniotis et al[25](#cas13949-bib-0025){ref-type="ref"} first described a new tumor vascular pattern, VM, which was totally diverse from existing tumor vascularization; in this pattern, tumor cells function as endothelial cells and form ECM‐like vessels that allow blood flow in the circulating system. Vascular mimicry structures can interconnect with local blood vessels, thereby providing substantial blood nutrition for tumor tissues.[26](#cas13949-bib-0026){ref-type="ref"} Multilineage differentiation plasticity is one of the characteristics of embryonic stem cells that is also evident during the development of VM. Normal tissue‐resident stem cells could differentiate into endothelial cells and participate in normal tissue vascularization, which is called transdifferentiation. The transdifferentiative capacity and differentiation plasticity of normal stem cells are also common characteristics of CSCs.[27](#cas13949-bib-0027){ref-type="ref"} In the statistical analysis we found that increased FZD2 expression was frequently observed in bigger tumors (diameter ≥5 cm), and in cell experiments that FZD2 played an essential role in the development of CSCs and the EMT phenotype of HCC cells. Therefore, we focused on VM formation to explore the further biological effect of FZD2‐mediated EMT. Results of in vitro and in vivo experiments indicated that FZD2 could sufficiently promote VM formation. Hence, FZD2 could be considered as a new target treatment to suppress VM and metastasis of HCC.

The most exciting discovery in our study is the undescribed identification of certain signaling pathways linked to FZD2 dysregulation, including the Hippo pathway and pluripotency of stem cells pathway. Except for the CSCs feature discussed above, the link between FZD2 and the Hippo pathway is meaningful and warrants investigation. The Hippo pathway is a key regulator of organ size control and tissue homeostasis and frequently deregulated in many human cancers, including HCC.[28](#cas13949-bib-0028){ref-type="ref"}, [29](#cas13949-bib-0029){ref-type="ref"}, [30](#cas13949-bib-0030){ref-type="ref"}, [31](#cas13949-bib-0031){ref-type="ref"} When Hippo signaling is deregulated, its downstream regulators YAP enter the nucleus and increase transcriptional activation of genes involved in excessive cell proliferation and diminished apoptosis, ultimately leading to rapid progression of tumorigenesis. Activation of YAP in mouse liver leads to the development of HCC.[32](#cas13949-bib-0032){ref-type="ref"}, [33](#cas13949-bib-0033){ref-type="ref"} Knockout MST1/2, upstream inhibitors of YAP, in mouse liver also leads to the development of HCC.[34](#cas13949-bib-0034){ref-type="ref"}, [35](#cas13949-bib-0035){ref-type="ref"} Moreover, the Hippo pathway components also regulate other divergent physiological processes, including cell differentiation, stem cell self‐renewal, reprogramming, and patterning.[6](#cas13949-bib-0006){ref-type="ref"}, [29](#cas13949-bib-0029){ref-type="ref"}, [36](#cas13949-bib-0036){ref-type="ref"} Recent studies suggested that the canonical Wnt/β‐Catenin pathway converged with the Hippo/YAP pathway to promote pluripotent stem cell features and tumorigenesis.[34](#cas13949-bib-0034){ref-type="ref"}, [37](#cas13949-bib-0037){ref-type="ref"}, [38](#cas13949-bib-0038){ref-type="ref"}, [39](#cas13949-bib-0039){ref-type="ref"} However, little attention was paid to the interaction between the noncanonical Wnt pathway and Hippo pathway. Here, we present pioneering research on a possible link between FZD2, a key transducer of the noncanonical Wnt pathway, and the Hippo‐YAP pathway. FZD2 engendered activation of YAP and inhibition of upstream regulators, including MST1/2 and LATS. Based on this evidence, we believe our present study broadens the potential therapeutic target of the Hippo‐YAP pathway to include FZD2 and sheds light on strategies for inhibiting this pathway for therapeutic benefit. However, additional studies are needed to confirm our hypothesis.

Taken together, our current study deepens our understanding of FZD2. First, FZD2 was found to be aberrantly upregulated in Chinese HCC patients with HBV infection. Second, by identifying numerous FZD2‐regulated pathways and novel downstream targets, combined with functional studies, we robustly defined the oncogenic role of FZD2 in HCC. Third, we report for the first time that FZD2‐induced EMT might promote VM and CSCs, and subsequently contribute to the progress and recurrence of HCC. Finally, this study revealed a promising correlation between the Hippo pathway and FZD2, thus establishing an extensive basis and providing a rationale for studying the role of FZD2 in HCC tumorigenesis.
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